PLUR
Pluri (PLUR)
$81
About Pluri (PLUR)
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Details
Daily high
$1.83
Daily low
$1.75
Price at open
$1.75
52 Week High
$5.68
52 Week Low
$1.45
Market cap
18.8M
Dividend yield
0.00%
Volume
5,142
Avg. volume
34,288
P/E ratio
-.61
Pluri News
Details
Daily high
$1.83
Daily low
$1.75
Price at open
$1.75
52 Week High
$5.68
52 Week Low
$1.45
Market cap
18.8M
Dividend yield
0.00%
Volume
5,142
Avg. volume
34,288
P/E ratio
-.61